-
Weak Data in Focus 08-01-2011
Monday, August 1, 2011 - 2:40pm | 1073Cusick's Corner Well the market initially thought that a deal on the Debt ceiling was very close to being made but the reality is that the data is weak and the market is taking notice. I spoke about that last week that we can see the debt, we can anticipate where it is going and the impact on...
-
Mylan Breaks Below 200-Day Moving Average at $22.37
Monday, August 1, 2011 - 10:59am | 83The moving averages track the previous price action in a stock. In this case, the 200-day moving average compiles the average share price of the last 200 trading days. Perspective: Price above the average is perceived as positive while price below the average is negative. Currently, Mylan (NYSE...
-
Benzinga's Volume Movers
Monday, August 1, 2011 - 10:07am | 127Allot Communications Ltd (NASDAQ: ALLT) shares moved up 7.35% to $15.91 at 10:05 am. The volume of ALLT shares traded was 219% higher than normal. ALLT reported upbeat Q2 results. Stamps.com Inc (NASDAQ: STMP) shares rose 4.06% to $17.43. The volume of STMP shares traded was 184% higher than...
-
AstraZeneca Announces U.S. Enrollment Opportunities for KODIAC Study to Investigate an Experimental Drug for Constipation from Opioids
Monday, August 1, 2011 - 10:01am | 77AstraZeneca (NYSE: AZN) today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation. The study, known as KODIAC, is a Phase III clinical trial examining an...
-
Forest Laboratories Sends Letter to Shareholders
Monday, August 1, 2011 - 8:49am | 341Forest Laboratories, Inc. (NYSE: FRX) today announced that its Board of Directors has sent a letter to all Forest shareholders in connection with the Company's Annual Meeting on August 18, 2011. The letter highlights Forest's strong financial performance, robust and diversified product pipeline and...
-
The Week Ahead, Morning Noteables August 1
Monday, August 1, 2011 - 8:46am | 304AM headlines: Sohu.com (SOHU) "Plus to Minus in the pre market - Contra trade - seems priced in - Looks good short for the moment with the overall strength in the broader pre market" Sohu.com reports Q2 EPS $1.21 vs. consensus $1.06 Reports Q2 revenue $198.7M vs. consensus $190.78M. Exceeds...
-
UPDATE: Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To $52
Monday, August 1, 2011 - 8:38am | 134Jefferies & Company has published a research report on Jazz Pharmaceuticals (NASDAQ: JAZZ) and has upgraded the company from Hold to Buy. In the report, Jefferies writes, "Xyrem pricing headroom has been apparent, but the recent volume growth has been a surprise -- and one we now feel has legs...
-
J.P. Morgan Maintains Overweight Rating On Merck & Co
Monday, August 1, 2011 - 8:24am | 114According to J.P. Morgan, Merck & Co (NYSE: MRK) reported inline 2Q EPS, the company announced an expanded restructuring program that represents a key positive. J.P. Morgan said that the initiative is expected to drive annual cost savings of $4.0-$4.6 bn by 2015 (vs. prior $3.5bn by 2012) and...
-
Hold These Funds Forever! Really? Forever?
Monday, August 1, 2011 - 8:16am | 877There was an article over at Seeking Alpha about a few dividend stocks that the author posits can be held forever. Investing magazines have had cover stories about funds to hold forever for as long as there have been investing magazines. The concept is fascinating; it would be great to buy six or...
-
Optimer Pharmaceuticals Reports Inducement Grants
Monday, August 1, 2011 - 8:02am | 137Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on July 29, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 215,250 shares of common stock to 42 new employees. Each stock option has an exercise...
-
ARIAD Announces That Merck Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the EU
Monday, August 1, 2011 - 7:38am | 131ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck (NYSE: MRK), has submitted a marketing authorization application for ridaforolimus with the European Medicines Agency. The submission occurred on July 29, 2011 and marks the start of Merck's global...
-
Deutsche Bank Updates 8/1
Monday, August 1, 2011 - 7:33am | 927Deutsche Bank made a number of updates in a research report published today. American Axle & Manufacturing (NYSE: AXL) had its rating reiterated at Hold. On Friday, AXL added 8.82% to its value to finish the week at $11.47. Tenneco (NYSE: TEN) had its rating reiterated at...
-
Teva Pharmaceutical Announces Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Monday, August 1, 2011 - 7:32am | 119Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ: ACTI) announced today initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment...
-
Jefferies Upgrades Jazz Pharmaceuticals To Buy, Raises PT To $52
Monday, August 1, 2011 - 6:02am | 28Jefferies & Company has upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Hold to Buy and has raised the price target from $29 to $52.
-
Mad Money Lightning Round: Cramer Likes PPL Corp
Monday, August 1, 2011 - 3:05am | 175On CNBC's Mad Money, Jim Cramer said during the Lightning Round that PPL Corp (NYSE: PPL) is “very reliable and very good and I'd buy it right here." For Exelixis (NASDAQ: EXEL), he said, "I think these companies are terrific bets and I want to be in this one." Cramer said that GlaxoSmithKline...